Vitality Watch

Dossier pubmed observational 21-aug-2026
Human cohort, case-control, or epidemiological association

Examination of DNAm PhenoAge as an epigenetic biomarker for perioperative risk in adult spinal deformity surgeries.

Key claim: In adult spinal deformity surgery, DNAm PhenoAge was associated with several postoperative adverse events and consistently improved model fit and reclassification versus chronological age, though AUC differences were not statistically significant.

Abstract

Epigenetic changes, such as DNA methylation (DNAm), offer a measure of biological age distinct from chronological age. DNAm PhenoAge is one such biomarker that is more strongly related to morbidity, mortality, and physical function than chronological age. More accurate risk stratification methods are needed for ASD surgeries, where complications remain difficult to predict with an increasingly aged population. A multicenter ASD registry was queried. DNAm PhenoAge was calculated as per Levine et al. (6). Multivariable logistic regression examined the associations of DNAm PhenoAge and chronological age with perioperative adverse events (AE). The relative improvements in model discrimination, fit, and classification performance were compared. Adjusted odds ratios compared the risk of 55 versus 75 years for each age metric. Laboratory data were available for 200 patients. Mean DNAm PhenoAge was lower than chronological (DNAm PhenoAge, 53.7 ± 18.1; chronological, 61.1 ± 15.4; p < 0.001; 95% CI, 6.3-8.5). DNAm PhenoAge models demonstrated numerically higher discrimination for all outcomes examined (AUC range, 0.701-0.823 vs. 0.671-0.767), although no DeLong comparisons were statistically significant (all p > 0.05). Model fit consistently favored DNAm PhenoAge (ΔAIC, 4.41-7.08), with NRI ranging from 0.198 to 0.500. For most adverse events, DNAm PhenoAge demonstrated adjusted odds ratios that were comparable to or greater than those observed for chronological age. In this exploratory study, DNAm PhenoAge demonstrated associations with several postoperative adverse events. Although differences in discrimination were not statistically significant, improvements were consistently observed across multiple complementary measures of model performance. The generally consistent direction of improved model performance suggests that DNAm PhenoAge warrants further study as a candidate biomarker for perioperative risk stratification (level of evidence, 3).

Why this matters

Most PhenoAge validation sits in population cohorts and disease-association studies; perioperative outcomes are a stricter test because the endpoint is a near-term, adjudicated clinical event rather than long-run mortality. This spinal deformity registry shows the familiar pattern seen in other surgical cohorts — PhenoAge adds reclassification signal over chronological age but doesn’t clear the AUC-significance bar — making it incremental evidence that epigenetic clocks sharpen but do not yet replace surgical risk tools.

Source

Link

Briefing card

Examination of DNAm PhenoAge as an epigenetic biomarker for perioperative risk in adult spinal deformity surgeries.
Stage: observational · pubmed · 21-aug-2026

If you are being risk-stratified before adult spinal deformity surgery, DNAm PhenoAge in this study added reclassification signal to chronological age but did not significantly improve overall discrimination of postoperative complications.

In adult spinal deformity surgery, DNAm PhenoAge was associated with several postoperative adverse events and consistently improved model fit and reclassification versus chronological age, though AUC differences were not statistically significant.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.1007/s11357-026-02481-8

build build 880 · 2bcef25 · 2026-11-18